Abcam, ab236051, Anti-Activin Receptor Type IA antibody [EPR4076(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Activin Receptor Type IA antibody. Carrier free. Suitable for IP, WB and reacts with Mouse, Human, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR4076(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab236051 is the carrier-free version of
ab155981
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Activin Receptor Type IA also known as ACVR1 or ALK2 is a type I receptor serine/threonine kinase. It has a mass of approximately 55 kDa. Activin Receptor Type IA is widely expressed in various tissues including skeletal muscle heart and central nervous system. It functions through the binding of ligands like activins and bone morphogenetic proteins (BMPs) which triggers intracellular signaling cascades important for cellular processes.
Biological function summary
Activin Receptor Type IA plays a significant role in several cellular activities including growth and differentiation. It operates as part of a receptor complex with type II receptors like ACVR2A protein which facilitates ligand binding and phosphorylation. Activin receptor is essential for the regulation of mesoderm induction and organ development notably in the skeletal and muscular systems. Its interaction with activin protein family members influences various developmental processes.
Pathways
Activin Receptor Type IA is an integral component of the TGF-beta signaling pathway and BMP pathway. These pathways are vital for embryonic development and tissue homeostasis. Activin receptor interacts with the SMAD family of proteins which mediate signal transduction to the nucleus influencing gene expression. Through these pathways it relates functionally to SMAD1 and SMAD2 proteins that contribute to cell proliferation and differentiation dynamics.
Activin Receptor Type IA is associated with fibrodysplasia ossificans progressiva (FOP) and cancer. Mutations in the ACVR1 gene can lead to abnormal bone growth seen in FOP commonly due to erroneous activation of the BMP signaling pathway. In some cancers the dysregulation of activin receptor signaling can alter cell proliferation rates placing it in connection with proteins involved in oncogenic processes. Targeting activin receptor pathways might offer therapeutic potential in certain diseases by modulating or restoring its normal signaling capability.